These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11205870)

  • 1. Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac.
    Wang M; Gorrell MD; McGaughan GW; Dickinson RG
    Life Sci; 2001 Jan; 68(7):785-97. PubMed ID: 11205870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic covalent adduct formation with zomepirac in the CD26-deficient mouse.
    Wang M; Gorrell MD; Abbott CA; Jaggi R; Marguet D; Dickinson RG
    J Gastroenterol Hepatol; 2002 Jan; 17(1):66-71. PubMed ID: 11895555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma.
    Bailey MJ; Dickinson RG
    Chem Res Toxicol; 1996; 9(3):659-66. PubMed ID: 8728513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile duct ligation promotes covalent drug-protein adduct formation in plasma but not in liver of rats given zomepirac.
    Wang M; Dickinson RG
    Life Sci; 2000 Dec; 68(5):525-37. PubMed ID: 11197750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of hepatocytes and liver homogenates in modelling in vivo formation of acyl glucuronide-derived drug-protein adducts.
    Bailey MJ; Dickinson RG
    J Pharmacol Toxicol Methods; 1999 Feb; 41(1):27-32. PubMed ID: 10507755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system.
    Bailey MJ; Worrall S; de Jersey J; Dickinson RG
    Chem Biol Interact; 1998 Sep; 115(2):153-66. PubMed ID: 9826947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of proliferation of HT-29 colon adenocarcinoma cells by carboxylate NSAIDs and their acyl glucuronides.
    Cannell GR; Vesey DA; Dickinson RG
    Life Sci; 2001 Nov; 70(1):37-48. PubMed ID: 11764005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo studies on acyl-coenzyme A-dependent bioactivation of zomepirac in rats.
    Olsen J; Li C; Bjørnsdottir I; Sidenius U; Hansen SH; Benet LZ
    Chem Res Toxicol; 2005 Nov; 18(11):1729-36. PubMed ID: 16300382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of the bile-exteriorized rat as a source of reactive acyl glucuronides: studies with zomepirac.
    King AR; Dickinson RG
    J Pharmacol Toxicol Methods; 1996 Nov; 36(3):131-6. PubMed ID: 8959578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats.
    Chen Q; Doss GA; Tung EC; Liu W; Tang YS; Braun MP; Didolkar V; Strauss JR; Wang RW; Stearns RA; Evans DC; Baillie TA; Tang W
    Drug Metab Dispos; 2006 Jan; 34(1):145-51. PubMed ID: 16251255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the metabolism of tolmetin to the chemically reactive acyl-coenzyme A thioester intermediate in rats.
    Olsen J; Li C; Skonberg C; Bjørnsdottir I; Sidenius U; Benet LZ; Hansen SH
    Drug Metab Dispos; 2007 May; 35(5):758-64. PubMed ID: 17303625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatobiliary transport of diflunisal conjugates and taurocholate by the perfused rat liver: the effect of chronic exposure of rats to diflunisal.
    Wang M; Dickinson RG
    Life Sci; 1998; 62(8):751-62. PubMed ID: 9489511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac.
    Hargus SJ; Martin BM; George JW; Pohl LR
    Chem Res Toxicol; 1995 Dec; 8(8):993-6. PubMed ID: 8605291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile.
    Grillo MP; Hua F
    Drug Metab Dispos; 2003 Nov; 31(11):1429-36. PubMed ID: 14570776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac.
    Smith PC; Langendijk PN; Bosso JA; Benet LZ
    Clin Pharmacol Ther; 1985 Aug; 38(2):121-7. PubMed ID: 3874742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of benoxaprofen and flunoxaprofen acyl glucuronides in covalent binding to rat plasma and liver proteins in vivo.
    Dong JQ; Liu J; Smith PC
    Biochem Pharmacol; 2005 Sep; 70(6):937-48. PubMed ID: 16046212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acyl glucuronide reactivity in perspective: biological consequences.
    Bailey MJ; Dickinson RG
    Chem Biol Interact; 2003 May; 145(2):117-37. PubMed ID: 12686489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil depletion protects against zomepirac-induced acute kidney injury in mice.
    Yamashita S; Oda S; Endo H; Tsuneyama K; Yokoi T
    Chem Biol Interact; 2018 Jan; 279():102-110. PubMed ID: 29154782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irreversible binding of zomepirac to plasma protein in vitro and in vivo.
    Smith PC; McDonagh AF; Benet LZ
    J Clin Invest; 1986 Mar; 77(3):934-9. PubMed ID: 3949982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy.
    Walker GS; Atherton J; Bauman J; Kohl C; Lam W; Reily M; Lou Z; Mutlib A
    Chem Res Toxicol; 2007 Jun; 20(6):876-86. PubMed ID: 17536843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.